PXL 770

Drug Profile

PXL 770

Alternative Names: PXL-770

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Poxel
  • Class Antihyperglycaemics; Hepatoprotectants
  • Mechanism of Action AMP activated protein kinase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes

Highest Development Phases

  • Phase I Non-alcoholic steatohepatitis; Type 2 diabetes mellitus

Most Recent Events

  • 05 Oct 2018 Pharmacodynamics data from preclinical trials in Non-alcoholic steatohepatitis released by Poxel
  • 05 Oct 2018 Pharmacokinetics and adverse events data from two phase I trials in Non-alcoholic steatohepatitis released by Poxel
  • 19 Sep 2018 Poxel plans a phase IIa proof-of-concept study for Non-alcoholic steatohepatitis and Nonalcoholic fatty liver disease in first quarter of 2019
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top